摘要
目的观察泰索帝联合顺铂方案治疗蒽环类耐药性晚期乳腺癌的疗效与安全性。方法2000年4月至2005年3月,以泰索帝联合顺铂方案治疗蒽环类耐药性晚期乳腺癌31例。泰索帝75 mg/m^2,静滴,第1天；顺铂75 mg/m^2,静滴,第1天加水化、利尿、止吐等治疗；21 d为1周期。本组中位化疗周期数为4(2～8)周期。结果31例均可评价疗效。完全缓解(CR)2例(6．5%),部分缓解(PR)15例(48．4%),稳定(SD)7例(22．6%),进展(PD)7例(22．6%),总有效率(CR+PR) 54．9%,中位肿瘤进展时间(TTP)5个月。1年生存率66．7%。主要毒性为恶心、呕吐和骨髓抑制。结论泰索帝和顺铂联合方案治疗蒽环类耐药性晚期乳腺癌疗效较好,使用方便,毒性反应较轻,是蒽环类耐药性乳腺癌的有效解救治疗方案。
Objective To evaluate the efficacy and safety of combination chemotherapy of Docetaxel （Taxotere, TXT） combined with cisplatin（DDP） for anthracycline （ANT）-resistant advanced breast cancer （ABC）. Methods From April 2000 to March 2005,31 patients with ANT-resistant advanced breast cancer were treated with combination chemotherapy of TXT and DDP. TXT 75 mg/m^2 and DDP 75 mg/m^2 were used on day 1 every three weeks. The median number of cycles was 4 （ range ： 2 ～ 8 cycles）. Results The overall combination chemotherapy response rate was 54.9% with a median time to progression of 5 months. One-year survival rate was 66.7%. The main side effects were gastrointestinal and hematologic toxicities, including grade 3 to 4 nausea and vomiting in 3 patients （9. 7% ） , leukopenia in 6 （ 19. 3% ）, and neutropenia in 3 （9.7%）. Conclusion Taxotere and displatin combination is active in the treatment for anthracycine-resistant advanced breast cancer patient with an acceptable toxicity, and may be a therapeutic alternative after anthracycline regimen has faild.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2006年第6期471-473,共3页
Chinese Journal of Oncology
关键词
多西紫杉醇
顺铂
蒽环类
乳腺肿瘤
Docetaxel
Cisplatin
Anthracycline
Breast neoplasms
